1,2-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Catalog No. :
ACROVY182
CAS No. :
2223050-13-1
Molecular Formula :
C11H19BN2O2
Molecular Weight :
222.10

IUPAC Name:1,2-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

1,2-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$1525.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1,2-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole
IUPAC Name1,2-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole
MDL No.MFCD28055187
Molecular FormulaC11H19BN2O2
Molecular Weight222.10
SMILESCC1(C)C(C)(C)OB(C2=CN(C)C(C)=N2)O1
InChI KeyVPJVMVYTRJQPOS-UHFFFAOYSA-N
Synonym1,2-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole;1H-Imidazole, 1,2-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.2223050-13-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACROVY182 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACROVY182 route product structure diagram
    ACROVY1822223050-13-1
Inquiry

2. ACROVY182 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACIZQN952 route compound structure diagram
    ACIZQN952850429-59-3 In Stock
  4. Then
  5. ACROVY182 route product structure diagram
    ACROVY1822223050-13-1
Inquiry

Comments (0)